Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Exscientia

- PMLiVE

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

- PMLiVE

Merck’s ezetimibe has ‘modest’ benefit when added to statins

Combination showed a reduction in cardiovascular events in patients with ACS

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

Triple therapy ‘might cure hep C in six weeks’

Phase II trials shows promise for Merck and Gilead drugs

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

Bristol-Myers Squibb (BMS) building

BMS taps F-star Alpha for immuno-oncology drug

Drug in development for breast and stomach cancers

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

Roche - Basel

Strong sales in breast cancer lift Roche revenues

New products Perjeta and Kadcyla lead growth

- PMLiVE

Pfizer’s palbociclib on track for early 2015 launch

Good news for the highly anticipated breast cancer drug

- PMLiVE

EMG appoints Merck and Boehringer directors as new officers

David Garmon-Jones is new chair and Zinta Krumins is vice chair

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

- PMLiVE

Janssen, AZ and Roche at ESMO

Companies present promising data on new cancer drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links